FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study |
| |
| Institution: | 1. Department of Surgery, Kansai Medical University Hirakata Hospital, Hirakata;2. Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu;3. Department of Gastroenterological Surgery, Osaka General Medical Center, Osaka;4. Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto;5. Department of Surgery, Fukuiken Saiseikai Hospital, Fukui;6. Department of Surgery, Kansai Rosai Hospital, Amagasaki;7. Department of Surgery, Osaka University, Suita;8. Department of Gastroenterology, Chiba Cancer Center, Chiba;9. Department of Radiology, Kobe Medical Center, Kobe;10. Department of Integrated Medicine, Kagawa University, Kita;11. Department of Surgery, Gifu Prefectural General Medical Center, Gifu;12. Department of Surgery, Kitakyushu General Hospital, Kitakyusyu;13. Second Department of Surgery, Hamamatsu University School of Medicine, Shizuoka;14. Department of Medical Oncology, Nagoya Memorial Hospital, Nagoya;15. Department of Surgery, Toho University Medical Center Sakura Hospital, Sakura;16. Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo;17. Department of Gastroenterological Surgery, Kumamoto University, Kumamoto;18. Department of Biostatistics, School of Public Health, Graduate School of Medicine and Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo;19. Tokai Central Hospital, Kagamihara;20. Cancer Center, Aichi Medical University, Nagakute, Japan |
| |
| Abstract: | BackgroundA targeted agent combined with chemotherapy is the standard treatment in patients with metastatic colorectal cancer (mCRC). The present phase III study was conducted to compare two doses of bevacizumab combined with irinotecan, 5-fluorouracil/leucovorin (FOLFIRI) in the second-line setting after first-line therapy with bevacizumab plus oxaliplatin-based therapy.Patients and methodsPatients were randomly assigned to receive FOLFIRI plus bevacizumab 5 or 10 mg/kg in 2-week cycles until disease progression. The primary end point was progression-free survival (PFS), and secondary end points included overall survival (OS), time to treatment failure (TTF), and safety.ResultsThree hundred and eighty-seven patients were randomized between September 2009 and January 2012 from 100 institutions in Japan. Baseline patient characteristics were well balanced between the two groups. Efficacy was evaluated in 369 patients (5 mg/kg, n = 181 and 10 mg/kg, n = 188). Safety was evaluated in 365 patients (5 mg/kg, n = 180 and 10 mg/kg, n = 185). The median PFS was 6.1 versus 6.4 months (hazard ratio, 0.95; 95% confidence interval CI] 0.75–1.21; P = 0.676), and median TTF was 5.2 versus 5.2 months (hazard ratio, 1.01; 95% CI 0.81–1.25; P = 0.967), respectively, for the bevacizumab 5 and 10 mg/kg groups. Follow-up of OS is currently ongoing. Adverse events, including hypertension and hemorrhage, occurred at similar rates in both groups.ConclusionBevacizumab 10 mg/kg plus FOLFIRI as the second-line treatment did not prolong PFS compared with bevacizumab 5 mg/kg plus FOLFIRI in patients with mCRC. If bevacizumab is continued after first-line therapy in mCRC, a dose of 5 mg/kg is appropriate for use as second-line treatment.Clinical trial identifierUMIN000002557. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
